Explore the NIHProtocol Details
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
02-DK-0022 |
Sponsoring Institute |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
No |
Population Exclusion(s) |
None |
Special Instructions |
Currently Not Provided |
Keywords |
Lipoatrophic Diabetes; |
Recruitment Keyword(s) |
Lipodystrophy; |
Condition(s) |
Lipodystrophy |
Investigational Drug(s) |
Metreleptin |
Investigational Device(s) |
None |
Intervention(s) |
Drug: Metreleptin |
Supporting Site |
|
Patients age greater than or equal to 6 months with significant lipodystrophy may be eligible for this study. Candidates will be screened with a physical examination and blood tests. Participants will be admitted to the NIH Clinical Center for 10 days for the following studies before beginning 12 months of leptin therapy:
- Insulin tolerance test -measures blood sugar levels after intravenous (IV) administration of insulin. Blood samples are collected through the IV tube at various intervals during the 1-hour test.
- Ultrasound of the liver and, if abnormalities are found, possibly liver biopsies.
- Fasting blood tests - to measure blood count, blood lipids and various hormones and assess liver function.
- Resting metabolic rate - to measure the amount of oxygen breathed at rest in order to calculate how many calories are required to maintain resting body functions.
- Magnetic resonance imaging of the liver and other organs, and of muscle and fat.
- Pelvic ultrasound in women - to detect ovarian cysts.
- Estimation of body fat - measurements of height, weight, waist, hip size, and skin folds over the arms and abdomen to estimate body fat content.
- Oral glucose tolerance test -measures blood sugar and insulin levels. The patient drinks a very sweet drink containing glucose (sugar), after which blood samples are collected through an IV tube in an arm vein at various intervals during the 3-hour test.
- Intravenous glucose tolerance test -measures tissue response to insulin and glucose after glucose injection and insulin infusion. Blood is collected over 3 hours to measure insulin and glucose levels.
- Appetite level and food intake - to measure hunger level and caloric intake. Patients are questioned about their hunger level, given a variety of foods they may choose to eat and questioned again at various intervals about hunger level. On another day, patients are given breakfast (usually a milkshake) and when they want to eat again, the appetite level and caloric intake study is repeated.
- Hormone function tests - the function of three hormones influenced by leptin (corticotropin-releasing hormone, thyrotropin-releasing hormone and luteinizing hormone-releasing hormone) are assessed. The hormones are injected intravenously and then blood samples are drawn.
- Questionnaire - patients complete a questionnaire about their activities and how they feel.
- 24-hour urine collections - to measure specific hormones, proteins and sugars excreted in the urine.
Additional studies may include blood tests for genetic studies of lipodystrophy, a muscle biopsy to study muscle proteins involved in regulating energy expenditure before and after leptin replacement, and examination of a surgical specimen (if available) to study molecules that may be involved in energy storage and use.
When the above tests are completed, leptin therapy begins. The drug is injected under the skin twice a day for 4 months and then once a day, if feasible. The dose is increased at the 1- and 2-month visits. Follow-up visits at 1, 2, 4, 6, 8 and 12 months after therapy starts include a physical examination, blood tests and a meeting with a dietitian. At the end of 12 months, all baseline studies described above are repeated. Patients record their symptoms weekly throughout the study. Those with diabetes measure their blood glucose levels daily before each meal and at bedtime.
Eligibility
INCLUSION CRITERIA:
All ethnic groups.
Males and females.
-Age greater than or equal to 6 months.
-Clinically significant lipodystrophy, identified by the study physician during the physical examination as an absence of fat outside the range of normal variation and/or identified as a disfiguring factor by the patient.
Circulating leptin levels less than 12.0 ng/ml in females and less than 8.0 ng/ml in males as measured by Linco assay on a specimen obtained after an overnight fast. In children ages 6 months - 5 years, a circulating leptin level of less than 6 ng/mL will be used. Leptin samples will be run through Millipore Laboratories, who use the Linco Assay, which has been the assay previously used to measure leptin levels throughout this study period.
Presence of at least one of the following metabolic abnormalities:
1. Presence of diabetes as defined by the 2007 ADA criteria
a. Fasting plasma glucose greater than or equal to 126 mg/dL, or
b. 2 hour plasma glucose greater than or equal to 200 mg/dL following a 75 gram (1.75gm/kg) oral glucose load, or
c. Diabetic symptoms with a random plasma glucose greater than or equal to 200 mg/dl
2. Fasting insulin greater than 30 micro units/ml.
3. Fasting hypertriglyceridemia greater than 200 mg/dL or postprandially elevated triglycerides greater than 500 mg/dL when fasting is clinically not indicated (e.g. in infants)
-Persons with impaired decision-making capacity and who may be unable to provide informed consent may participate in this study per the discretion of the Principal Investigator.
EXCLUSION CRITERIA:
Pregnant women, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.
Exclusions for underlying diseases likely to increase side effects or hinder objective data collection:
- Known infectious liver disease
-Known HIV infection
- Current alcohol or substance abuse
- Psychiatric disorder impeding competence or compliance
- Active tuberculosis
- Use of anorexiogenic drugs
- Other condition(s) which in the opinion of the clinical investigators would impede completion of the study
-Subjects who have known hypersensitivity to E. Coli derived proteins.
-Subjects with acquired lipodystrophy and a hematologic abnormality such as neutropenia and/or lymphadenopathy
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information: |
| Phillip Gorden, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health 10 CENTER DRIVE BETHESDA MD 20892-1770 (301) 402-7340 gordenp@extra.niddk.nih.gov |
Elaine K. Cochran, C.R.N.P. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health BG 10-CRC RM 5-3961 10 CENTER DR BETHESDA MD 20814 (301) 496-2718 elainer@intra.niddk.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00025883
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
